GENE ONLINE|News &
Opinion
Blog

2020-09-12| Asia-Pacific

Relaxation of CBD Restriction Sparks Controversy

by Judy Ya-Hsuan Lin
Share To

THC Global Group Limited embraces an interim Therapeutic Goods Administration (TGA) decision to down schedule cannabidiol (CBD) medicines to Schedule 3 to allow easier access of low-dose CBD without prescriptions.

By Judy Ya-Hsuan Lin

THC Global’s Southport Facility is one of the world’s largest pharmaceutical GMP cannabis manufacturing facilities. Because they own Crystal Mountain, a fast-growing hydroponics equipment wholesaler, they can supply wholesalers and retailers in Europe and North America’s rapidly expanding cannabis sector. The CBD market analysis company Brightfield Group predicted that the cannabis industry’s value would hit 22 billion by 2022. Although the down-scheduling ensures a well-documented safety profile, higher accessibility and better affordability to patients, the TGA decision sparks controversy over two parties holding different opinions on the expanding use of CBD.

The THC decision to expand CBD legalizes many activities and conveniences in daily life, but limited clinical evidence demonstrates the extent of therapeutic effectiveness and safety for individuals and patients. Thus, the decision poses potential suspicion. Zsolt Csonka, the founder of Adriaen Block restaurant located in Astoria, New York, uses CBD-contained concomitants in his dishes to optimize customers’ tasting experience.

Besides, he shared his experience that it usually takes 4-5 shots of Whiskey for people to feel relaxed but only two shots containing CBD to impose the same effect. Dr. Chris Freeman, the Pharmaceutical Society of Australia national president, told the Australian Journal of Pharmacy an opposing opinion. He is concerned about the lack of clinical evidence of low-dose CBD’s therapeutic efficacy for patients and the current absence of enough information to ensure patients access these medicines appropriately.

Related Article: Weekly in Asia(0414-0420)

References:

https://www.proactiveinvestors.com.au/companies/news/928601/thc-global-welcomes-interim-tga-decision-to-down-schedule-cbd-medicines-to-allow-pharmacy-access-without-prescription-928601.html

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
The FDA Issued its First Formal Warning to Companies Selling Delta-8 THC Products
2022-05-05
MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer’s in the EU and UK
2022-04-05
An Undersea Chemical Factory: Toxins from the Cone Snail As the Next Painkiller
2022-03-30
LATEST
Pfizer To Invest $1.26 Billion In Irish Plant, Forms New Vant Company Targeting Inflammation
2022-12-02
Scientists Identify New Genetic Variant Related to Obesity
2022-12-01
Micronbrane Medical Aspires to Further Clinical Collaboration Following the Successful Series A Funding
2022-12-01
FDA Revokes Authorization Of Eli Lilly’s COVID-19 Antibody
2022-12-01
Eisai Unveils Lecanemab Data Following Reports of Second Alzheimer’s Patient Death
2022-11-30
New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio
2022-11-30
Gland Pharma Dispels Rumors Of Fosun Sale, Acquires Cenexi In Separate Development
2022-11-30
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!